Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.
Nishiguchi G, Mascibroda LG, Young SM, Caine EA, Abdelhamed S, Kooijman JJ, Miller DJ, Das S, McGowan K, Mayasundari A, Shi Z, Barajas JM, Hiltenbrand R, Aggarwal A, Chang Y, Mishra V, Narina S, Thomas M, Loughran AJ, Kalathur R, Yu K, Zhou S, Wang X, High AA, Peng J, Pruett-Miller SM, Daniels DL, Urh M, Shelat AA, Mullighan CG, Riching KM, Zaman GJR, Fischer M, Klco JM, Rankovic Z. Nishiguchi G, et al. Among authors: zaman gjr. Nat Commun. 2024 Jan 16;15(1):482. doi: 10.1038/s41467-024-44698-1. Nat Commun. 2024. PMID: 38228616 Free PMC article.
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.
Zanini E, Forster-Gross N, Bachmann F, Brüngger A, McSheehy P, Litherland K, Burger K, Groner AC, Roceri M, Bury L, Stieger M, Willemsen-Seegers N, de Man J, Vu-Pham D, van Riel HWE, Zaman GJR, Buijsman RC, Kellenberger L, Lane HA. Zanini E, et al. Among authors: zaman gjr. Front Oncol. 2024 Aug 9;14:1447807. doi: 10.3389/fonc.2024.1447807. eCollection 2024. Front Oncol. 2024. PMID: 39184047 Free PMC article.
The bacterial lysate OM-85 engages Toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cells.
Khameneh HJ, Bolis M, Ventura PMO, Cassanmagnago GA, Fischer BA, Zenobi A, Guerra J, Buzzago I, Bernasconi M, Zaman GJR, Rinaldi A, Moro SG, Sallusto F, Baulier E, Pasquali C, Guarda G. Khameneh HJ, et al. Among authors: zaman gjr. Mucosal Immunol. 2024 Jun;17(3):346-358. doi: 10.1016/j.mucimm.2024.02.010. Epub 2024 Mar 4. Mucosal Immunol. 2024. PMID: 38447907 Free article.
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.
Kooijman JJ, van Riel WE, Dylus J, Prinsen MBW, Grobben Y, de Bitter TJJ, van Doornmalen AM, Melis JJTM, Uitdehaag JCM, Narumi Y, Kawase Y, de Roos JADM, Willemsen-Seegers N, Zaman GJR. Kooijman JJ, et al. Among authors: zaman gjr. Front Oncol. 2022 Sep 14;12:953013. doi: 10.3389/fonc.2022.953013. eCollection 2022. Front Oncol. 2022. PMID: 36185300 Free PMC article.
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG, Buijs-Gladdines JGCAM, Cordo' V, Debets DO, Smits WK, Chen Z, Dylus J, Zaman GJR, Altelaar M, Oshima K, Bornhauser B, Bourquin JP, Cools J, Ferrando AA, Vormoor J, Pieters R, Vormoor B, Meijerink JPP. van der Zwet JCG, et al. Among authors: zaman gjr. Leukemia. 2021 Dec;35(12):3394-3405. doi: 10.1038/s41375-021-01291-5. Epub 2021 May 18. Leukemia. 2021. PMID: 34007050 Free article.
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
Grobben Y, de Man J, van Doornmalen AM, Muller M, Willemsen-Seegers N, Vu-Pham D, Mulder WR, Prinsen MBW, de Wit J, Sterrenburg JG, van Cauter F, den Ouden JE, van Altena AM, Massuger LF, Uitdehaag JCM, Buijsman RC, Zaman GJR. Grobben Y, et al. Among authors: zaman gjr. Front Immunol. 2021 Jan 28;11:609490. doi: 10.3389/fimmu.2020.609490. eCollection 2020. Front Immunol. 2021. PMID: 33584686 Free PMC article.
65 results